Targeting Farnesoid X Receptor in Tumor and the Tumor Microenvironment: Implication for Therapy
M Nenkov, Y Shi, Y Ma, N Gaßler, Y Chen - International journal of …, 2023 - mdpi.com
The farnesoid-X receptor (FXR), a member of the nuclear hormone receptor superfamily, can
be activated by bile acids (BAs). BAs binding to FXR activates BA signaling which is …
be activated by bile acids (BAs). BAs binding to FXR activates BA signaling which is …
[HTML][HTML] Flow cytometry in acute myeloid leukemia and detection of minimal residual disease
Q Cai, H Lan, D Yi, B Xian, L Zidan, J Li, Z Liao - Clinica Chimica Acta, 2024 - Elsevier
Acute myeloid leukemia (AML) is a common type of acute leukemia (AL), belonging to
malignant tumors of the hematopoietic system with the characteristics of rapid disease …
malignant tumors of the hematopoietic system with the characteristics of rapid disease …
Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer
There is an urgent need to fully understand the biology of third generation EGFR‐tyrosine
kinase inhibitors (EGFR‐TKIs), particularly osimertinib, and to develop mechanism‐driven …
kinase inhibitors (EGFR‐TKIs), particularly osimertinib, and to develop mechanism‐driven …